AI Summary & Key Takeaways
AI InsightHowever, further large-scaled studies and clinical trials are necessary to support these in vitro data.
📌 3 Key Takeaways
Abstract
The aim of this study was to detect the in vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from blood cultures at Ataturk Training and Research Hospital, Izmir, Turkey between 2006-2010. A total of 64 MRSA clinical isolates were included in the study, and daptomycin susceptibility were investigated by E-test (AB bioMerieux, Sweden). The identification of the MRSA isolates was based on conventional microbiological methods and an additional automated identification system (Phoenix 100, BD Diagnostic Systems, USA). Etest strips were applied to the surface of Mueller-Hinton agar plates and incubated at 35°C in ambient air for 18 to 24 hours. Strains with a MIC value of ≤ 1 μg/ml were accepted as susceptible to daptomycin. In our study all of the 64 MRSA isolates were found susceptible to daptomycin (MIC ≤ 1 μg/ml). The $MIC _{50}, MIC _{90}$ and MIC ranges were detected as 0.125, 0.5 and 0.125-0.5 μg/ml, respectively. Only a single isolate yielded MIC value of 1 μg/ml. As a result daptomycin was found to be very active against MRSA strains in vitro. Our findings suggested that daptomycin might be a suitable alternative agent for treating bacteremia caused by MRSA. However, further large-scaled studies and clinical trials are necessary to support these in vitro data.